- Open Access
Impact of obesity on survival in COVID-19 ARDS patients receiving ECMO: results from an ambispective observational cohort
Annals of Intensive Care volume 11, Article number: 157 (2021)
Since March 2020, health care systems were importantly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, with some patients presenting severe acute respiratory distress syndrome (ARDS), requiring extra-corporeal membrane oxygenation (ECMO). We designed an ambispective observational cohort study including all consecutive adult patients admitted to 5 different ICUs from a university hospital. The main objective was to identify the risk factors of severe COVID-19 ARDS patients supported by ECMO associated with 90-day survival.
Between March 1st and November 30th 2020, 76 patients with severe COVID-19 ARDS were supported by ECMO. Median (interquartile range IQR) duration of mechanical ventilation (MV) prior to ECMO was of 6 (3–10) days. At ECMO initiation, patients had a median PaO2:FiO2 of 71 mmHg (IQR 62–81), median PaCO2 of 58 mmHg (IQR 51–66) and a median arterial pH of 7.33 (IQR 7.25–7.38). Forty-five patients (59%) were weaned from ECMO. Twenty-eight day, 60-day and 90-day survival rates were, respectively, 92, 62 and 51%. In multivariate logistic regression analysis, with 2 models, one with the RESP score and one with the PRESERVE score, we found that higher BMI was associated with higher 90-day survival [odds ratio (OR): 0.775 (0.644–0.934), p = 0.007) and 0.631 (0.462–0.862), respectively]. Younger age was also associated with 90-day survival in both models [OR: 1.1354 (1.004–1.285), p = 0.044 and 1.187 (1.035–1.362), p = 0.014 respectively]. Obese patients were ventilated with higher PEEP than non-obese patients and presented slightly higher respiratory system compliance.
In this ambispective observational cohort of COVID-19 severe ARDS supported by ECMO, obesity was an independent factor associated with improved survival at 90-day.
Since March 2020, Europe and France health care systems were importantly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak. Although most patients infected by coronavirus disease 2019 (COVID-19) present mild or moderate symptoms, about 10% will need hospitalization and 1.5% will require intensive care unit (ICU) hospitalization. Among them, around 70% need respiratory support by mechanical ventilation (MV) [1,2,3,4], and present with moderate to severe acute respiratory distress syndrome (ARDS).
In non-COVID-19 patients presenting with severe ARDS, extra-corporeal membrane oxygenation (ECMO) is a potentially life-saving strategy [5,6,7,8], when refractory hypoxemia or injurious mechanical ventilation parameters persists, despite low tidal volume ventilation associated with continuous neuromuscular blockers infusion and prolonged and repeated prone positioning. The initial reports of ECMO use in COVID-19 patients showed high mortality rates and raised concerns regarding the indication of the technique in this disease . However, international organizations (ELSO, ECMOnet) recommended and proposed ECMO guidelines for COVID-19 ARDS patients, with similar indications as for other ARDS etiologies based on EOLIA criteria [10,11,12]. Of note, ECMO support may be no more indicated in case of overwhelmed health care system. Rapidly, numerous cohorts with high number of patients and similar outcomes as non-COVID-19 ARDS supported by veno-venous ECMO (vvECMO) were published [13,14,15,16]. These results are important as the worldwide pandemic justifies optimal utilization of scarce resources, and the use of treatment or techniques that would secondarily appear futile should be avoided.
To better identify the population of patients that could benefit from the technique, we planned to identify the prognostic factors associated with survival in severe COVID-19 ARDS patients supported by ECMO.
Materials and methods
Study design and setting
We conducted a single-center ambispective observational cohort study including all consecutive adult patients admitted to the tertiary University Hospital of Assistance Publique-Hôpitaux de Marseille France, constituted of 5 different ICU units, with a diagnosis of confirmed COVID-19 associated pneumonia, documented by at least one real-time RT PCR test in nasopharyngeal swabs, and supported by ECMO for severe ARDS.
Among the 5 ICUs of our institute, one is the referral ECMO center of an area of 5 million inhabitants, has an ECMO mobile team available 24 h per day to cannulate and bring back to our hospital all patients from the referring hospitals. We used previously published criteria to indicate ECMO support .
The inclusion period covered the two first waves of the outbreak: from March 1st 2020 to May 31th 2020 for the first wave, and from September 1st 2020 to November 30th 2020 for the second wave.
This study was approved by the local Ethics Commission (2020-53) and the French Society of Anesthesia and Critical Care (00010254-2020-262). According to French law, the informed consent was not required due to the design of the study.
Data collection and outcomes
For the retrospective part of the study (first wave) data were collected through patients’ medical files, during the second wave the data were collected prospectively. We collected demographic characteristics including body mass index (BMI), comorbidities evaluated through Charlson score calculation, clinical presentation at ICU admission and severity scores [Simplified Acute Physiology score (SAPS II), Sequential Organ Function (SOFA)]. Specific treatments for COVID-19 and ICU therapies before ECMO support were also reported. When patients were transferred from referring hospitals by the ECMO mobile team, these data were retrieved from the initial ICU. Obesity was defined as a BMI superior or equal to 30 kg/m2. Ventilatory parameters, last blood-gas values before ECMO support were also collected, and we calculated for each patient different validated scores to predict mortality in ECMO patients: the RESP score  (Respiratory Extracorporeal Membrane Oxygenation Survival Prediction Score), the ECMO Net score , the PRESERVE score  (PRedictiong dEath for SEvere ARDS on veno-venous ECMO), the SOFA (Sequential Organ Function) score. Patients were then followed for 90 days since the first day of ICU admission and the following outcomes were collected: survival at day 28, day 60 and day 90, as well as date of ECMO weaning, MV duration, length of stay in ICU and in hospital. The occurrence of severe bleeding (defined by need of ≥ 2 red packed cells over 24 h), severe hemolysis (requiring ECMO circuit change), complications during the ECMO support (ventilatory-acquired pneumonia, bacteremia and septic shock, heparin-induced thrombocytopenia, arterial or venous thrombosis) and during the ICU stay [need for renal replacement therapy, reactive hemophagocytic syndrome defined according to the Saint-Antoine’s score , viral reactivations defined by positive viral load detected by PCR of herpes simplex virus (HSV) and cytomegalovirus (CMV), and invasive aspergillosis] were recorded.
Data are expressed as median and interquartile range (IQR) or numbers and percentage (%). We compared demographics data and pre-ECMO characteristics according to the 90-day post-ICU admission survival. Continuous variables were compared using the Student’s T-test. Categorical variables were compared using the Chi-square or Fisher’s exact tests. After testing collinearity, variables with p values < 0.1 in univariate analysis were entered in the multivariate logistic regression model. Results are expressed as odds ratios (OR) with 95% confidence intervals, and p values. The overall fit of the model was evaluated by Hosmer–Lemeshow test. We used two multivariate models, one for each predictive survival score under ECMO, to avoid collinearity as some variables are common in both scores. Independent prognostic factors of 90-day survival identified by multivariate logistic regression were used to dichotomize population and to construct Kaplan–Meier cumulative survival curves. Then, curves were compared with the log-rank test. We also split our cohort in two groups, obese and non-obese patients, and compared patients’ characteristics, severity and ECMO prognosis scores, as well as treatments received, delay from ICU admission to intubation and to ECMO therapy, respiratory mechanics and blood-gas values before ECMO. 73 patients were included in this analysis, 3 patients were excluded because of missing data for BMI. All statistical analyses were done using SPSS (IBM SPSS Statistics 20).
Between March 1st and November 30th 2020, 76 patients with severe COVID-19 ARDS were supported by ECMO, 77 (99%) by vvECMO and 1 patient by veno-arterial ECMO. Twenty-three patients (30%) were admitted during the first wave and 53 (70%) during the second wave. Patients’ main characteristics are presented in Tables 1 and 2. Concerning specific treatments, all patients of the second wave received dexamethasone at the dosage of 6 mg per day or equivalent doses of corticosteroids, but only one patient of the first wave, following the national management recommendations for SARS CoV-2 pneumonia : overall, 67% of the cohort received dexamethasone or equivalent.
Median time from ICU admission to ECMO initiation was 10.5 days (7–13) and median duration of MV prior to ECMO of 6 days (3–10). Of note, 75 patients (98.7%) had at least one session of prone positioning before ECMO. At ECMO initiation, patients had a median PaO2:FiO2 of 71 (62–81) mmHg, PaCO2 of 58 mmHg (51–66) and arterial pH of 7.33 (7.25–7.38). Before ECMO, patients were ventilated in volume-controlled mode with a positive end-expiratory pressure (PEEP) of 12 (9.5–14) cmH2O, a plateau pressure (Pplat) of 28 (25–30) cmH2O for a tidal volume (TV) of 5.8 (5.1–6.2) mL/kg of predicted body weight. Respiratory system static compliance was 23 (16.7–28.6) mL/cmH2O.
Forty-five patients were weaned from ECMO. Among them, five patients (11%) required a second ECMO run. ECMO final weaning rate was 59%, 7 patients (15.5%) died after decannulation. ECMO duration was 18 (11–31.5) days. Twenty-eight day, 60-day and 90-day survival rates were, respectively, 92, 62 and 51%. Main causes of death were septic shock (35%), hemorrhagic shock (32%) and intractable respiratory failure (16%). Complications occurring during the ECMO support are described in Tables 1 and 2.
Univariate analysis regarding 90-day survival is provided in Table 2. Factors associated with 90-day survival were younger age, higher BMI and lower Charlson score. Of note, time from ICU admission to intubation [2 days (0–5) in survivors versus 4 days (1–7) in non-survivors, p = 0.02] and time to ECMO cannulation [9 days (4–11) in survivors versus 11 (8–14) in non-survivors, p = 0.02] were shorter in 90-day survivors.
Patients from the first wave had a better prognosis [78.2% survivors at day 90 among patients from the first wave versus 39.6% among patients from the second wave, p = 0.002]. We did not find any difference in ventilatory parameters before ECMO between the survivors and the non-survivors. Concerning the predictive survival scores, the RESP score and the PRESERVE score were significantly different between survivors and non-survivors at day 90.
To determine the independent factors predicting mortality at day 90, we used two models in multivariate logistic regression analysis: model A with the RESP score and model B with the PRESERVE score because of collinearity between those variables (r = − 0.598, p < 0.001) (Table 3). Only BMI and age in the two models were associated with 90-day survival.
29 patients were obese in this cohort, with a higher proportion of obese patients in the survivors at day 90 [21 patients (53.8%) versus 8 patients (23.8%), p = 0.008]. These data are shown in Table 2. The median BMI of obese patients among the survivors at day 90 was 34.8 kg/m2 (31.1–46.9), which is higher from the median BMI of the whole survivors at day 90 which is 30.5 kg/m2 (24.2–35): there was 52% of patients with grade 1 obesity, 43% with grade 2 obesity and 5% with grade 3. Kaplan–Meier cumulated survival curves according to the presence of obesity were significantly different (Fig. 1, p = 0.006), the survival was also different when comparing the different obesity grades (Additional file 1: Fig. S1, p = 0.003).
Therefore, we compared obese and non-obese patients’ characteristics (Table 4). Obese patients were ventilated with higher PEEP than non-obese patients [14 (10–15) vs. 10 (8–12) cmH2O; p < 0.001] with comparable Pplat, 29 (25–31) vs. 28 (25–30) cmH2O, respectively (p = 0.923) and a trend to higher compliance of respiratory system in obese patients as compared with non-obese patients, respectively, 26.2 (21–39.1) and 23 (15.5–27.3) mL/cmH2O (p = 0.07). Obese patients had also a shorter delay from ICU admission to intubation (2 (0–4) days versus 4 (1–7) days in non-obese patients, p = 0.048) and to ECMO implantation [9 (4–11) days versus11 (8–14.5), p = 0.02]. Of note, obese patients were subjected before ECMO implantation, to a slightly higher mechanical power as compared with the non-obese patients, respectively, 20.3 (17.7–29.7) J/min and 17.7 (14.07–22.22) J/min (p = 0.06).
In this monocentric cohort of 76 consecutive patients with COVID 19 severe ARDS requiring ECMO, the 90-day survival was 51%. The independent predictors of 90-day survival were younger age and higher BMI.
Despite the preoccupying initial survival results displayed in the literature , most other important cohorts published to date find similar mortality rates as ours among ECMO COVID-19 patients, between 31 and 51% [13,14,15,16, 22,23,24,25]. When selection criteria are strict, survival rates of COVID 19 severe ARDS patients are closed to those reported in the early ECMO arm of the EOLIA trial  and very similar to severe ARDS patients supported by ECMO for influenza. In our cohort, as in another cohort published , survival was different over time, between the two waves, with 90-day survival being of 78% during the first wave and 39% during the second. This higher rate of mortality during the 2nd wave is unexplained, it could be related to a relative lower burden of the ICUs during the first wave in our region, or to highest severity of the patients who were unresponsive to dexamethasone.
We then analyzed the factors predicting 90-day mortality in our cohort, and evaluated the accuracy of previously validated ECMO survival prediction scores on COVID-19 patients.
The RESP and the PRESERVE scores were discriminating for 90-day survival, however in univariate analysis only. Another study by Supady et al.  evaluated these scores and found AUROC in COVID-19 patients of 0.604, 0.548 and 0.602 for the RESP, the PRESERVE and the SOFA score, respectively. Indeed, the relative homogeneity of COVID 19 severe ARDS patients (age, gender, comorbidities, organ failure involvement) could lead to less accuracy of survival scores. Thus, these scores cannot be recommended alone to indicate ECMO, but they provide helps for clinician decision. The decision to initiate ECMO should be taken on a bundle of arguments of which the scores are part, by a trained multidisciplinary team .
Several determinants of the prognosis of ECMO patients have been described : first demographic characteristics with in the front-line, age, which has been found as a factor influencing mortality in our cohort, and in other cohorts of COVID-19 patients under ECMO [13, 14, 23, 25, 30, 31]. Second, the number of organ dysfunctions before ECMO impacts prognosis in particular acute renal failure  and hyperlactatemia . Third, respiratory mechanics and management before ECMO are also classical prognostic factors. We did not find differences in respiratory mechanics between 90-day survivors and non-survivors probably due to the selection of the patients and the same phenotype with low respiratory system compliance. Of note, an earlier ECMO implantation could be associated with a better prognosis [25, 36].
Interestingly, we found that obesity was associated with 90-day survival. This result might seem surprising as obesity is a well-recognized serious risk factor for ICU admission, mechanical ventilation and mortality in COVID-19 [32,33,34,35,36]. Some authors hypothesized that this increased severity is may be due to adipose tissue being a reservoir for COVID-19, thus slowing down viral clearance [37, 38] and to chronic inflammatory state displayed in obese patients.
However, in non-COVID-19 patients, an “obesity paradox” has been described with an increased risk for developing pneumonia and ARDS in obese patients but no increase in mortality, or even better ICU survival rates than underweight patients in some series [39,40,41,42]. Kon et al.  hypothesized that this better survival in obese patients could be the consequence of the relative early lung failure due to altered respiratory mechanics (altered chest wall compliance, increase in intra-abdominal pressure, lung-volume reduction ), leading at the time of ECMO initiation to less lung parenchymal lesions and to faster recovery. Our results are consistent with this hypothesis with shorter time from ICU admission to intubation and ECMO in obese patients, and with a trend to better compliance with higher PEEP levels.
This study has several limitations. First it is a monocentric and partly retrospective study, making our results difficult to extrapolate to other ICUs. Second, our cohort display a relatively small number of patients, leading to difficulties of interpretation for univariate and multivariate analysis. Indeed, small samples can lead to lack of power and some risk factors could have been missed or under-estimated. Third, we did not test biological data associated with COVID-19 prognosis (CRP, d-dimers, ferritin, interleukin-6, lymphocyte ratio).
In this French monocentric cohort of COVID-19 severe ARDS patients requiring ECMO, obesity was an independent factor associated with improved 90-day survival. Further studies are warranted to confirm these results.
Availability of data and materials
The datasets generated or analyzed during this study are available from the corresponding author on reasonable request.
Severe acute respiratory syndrome coronavirus 2
Intensive care unit
Acute respiratory distress syndrome
Extracorporeal membrane oxygenation
Body mass index
- RESP score:
Respiratory Extracorporeal Membrane Oxygenation Survival Prediction Score 
- PRESERVE score:
PRedictiong dEath for SEvere ARDS on Veino-veinous ECMO score
- SOFA score:
Sequential Organ Function score
Herpes simplex virus
Positive end-expiratory pressure
Area under the receiver operating characteristic
COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60–73.
Roedl K, Jarczak D, Thasler L, Bachmann M, Schulte F, Bein B, et al. Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: a multicentric study in Germany. Aust Crit Care. 2021;34(2):167–75.
Murthy S, Archambault PM, Atique A, Carrier FM, Cheng MP, Codan C, et al. Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. CMAJ Open. 2021;9(1):E181–8.
Wendel Garcia PD, Fumeaux T, Guerci P, Heuberger DM, Montomoli J, Roche-Campo F, et al. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine. 2020;25:100449.
Peek GJ, Clemens F, Elbourne D, Firmin R, Hardy P, Hibbert C, et al. CESAR: conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure. BMC Health Serv Res. 2006;6(1):163.
Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965–75.
Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Jüni P, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. JAMA. 2018;320(21):2251–9.
Munshi L, Telesnicki T, Walkey A, Fan E. Extracorporeal Life support for acute respiratory failure. A systematic review and metaanalysis. Ann Am Thorac Soc. 2014;11(5):802–10.
Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. J Crit Care. 2020;58:27–8.
World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Pediatr Med Rodz. 2020;16(1):9–26.
Rajagopal K, Keller SP, Akkanti B, Bime C, Loyalka P, Cheema FH, et al. Advanced pulmonary and cardiac support of COVID-19 patients: emerging recommendations from ASAIO—a “living working document.” ASAIO J. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217129/. Accessed 16 May 2021.
Badulak J, Antonini MV, Stead CM, Shekerdemian L, Raman L, Paden ML, et al. Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the extracorporeal life support organization. ASAIO J. 2021;67(5):485–95.
Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020;396(10257):1071–8.
Lebreton G, Schmidt M, Ponnaiah M, Folliguet T, Para M, Guihaire J, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respir Med. 2021. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00096-5/abstract. Accessed 27 May 2021.
Diaz RA, Graf J, Zambrano JM, Ruiz C, Espinoza JA, Bravo SI, et al. ECMO for COVID-19-associated severe ARDS in Chile: a nationwide incidence and cohort study. Am J Respir Crit Care Med. 2021. https://doi.org/10.1164/rccm.202011-4166OC.
Schmidt M, Hajage D, Lebreton G, Monsel A, Voiriot G, Levy D, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med. 2020;8(11):1121–31.
Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The respiratory extracorporeal membrane oxygenation survival prediction (RESP) score. Am J Respir Crit Care Med. 2014;189(11):1374–82.
Pappalardo F, Pieri M, Greco T, Patroniti N, Pesenti A, Arcadipane A, et al. Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: the ECMOnet score. Intensive Care Med. 2013;39(2):275–81.
Schmidt M, Zogheib E, Rozé H, Repesse X, Lebreton G, Luyt C-E, et al. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Intensive Care Med. 2013;39(10):1704–13.
Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome: score for reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20.
Coronavirus SARS-CoV-2: recommandations thérapeutiques (17/06/2020). https://www.hcsp.fr/Explore.cgi/AvisRapportsDomaine?clefr=866. Accessed 28 May 2021.
Lorusso R, Combes A, Coco VL, De Piero ME, Belohlavek J. ECMO for COVID-19 patients in Europe and Israel. Intensive Care Med. 2021;47(3):344–8.
Jacobs JP, Stammers AH, Louis JS, Hayanga JWA, Firstenberg MS, Mongero LB, et al. Multi-institutional analysis of 100 consecutive patients with COVID-19 and severe pulmonary compromise treated with extracorporeal membrane oxygenation: outcomes and trends over time. ASAIO J. 2021;67(5):496–502.
Domecq JP, Lal A, Sheldrick CR, Kumar VK, Boman K, Bolesta S, et al. Outcomes of patients with coronavirus disease 2019 receiving organ support therapies: the international viral infection and respiratory illness universal study registry. Crit Care Med. 2021;49(3):437–48.
Supady A, Taccone FS, Lepper PM, Ziegeler S, Staudacher DL, Supady A, et al. Survival after extracorporeal membrane oxygenation in severe COVID-19 ARDS: results from an international multicenter registry. Crit Care. 2021;25(1):90.
Broman LM, Eksborg S, Coco VL, De Piero ME, Belohlavek J, Lorusso R. Extracorporeal membrane oxygenation for COVID-19 during first and second waves. Lancet Respir Med. 2021. https://doi.org/10.1016/S2213-2600(21)00262-9.
Supady A, DellaVolpe J, Taccone FS, Scharpf D, Ulmer M, Lepper PM, et al. Outcome prediction in patients with severe COVID-19 requiring extracorporeal membrane oxygenation—a retrospective international multicenter study. Membranes. 2021;11(3):170.
Murugappan KR, Walsh DP, Mittel A, Sontag D, Shaefi S. Veno-venous extracorporeal membrane oxygenation allocation in the COVID-19 pandemic. J Crit Care. 2021;61:221–6.
Rozencwajg S, Pilcher D, Combes A, Schmidt M. Outcomes and survival prediction models for severe adult acute respiratory distress syndrome treated with extracorporeal membrane oxygenation. Crit Care. 2016;20(1):392.
Marullo AG, Cavarretta E, Biondi Zoccai G, Mancone M, Peruzzi M, Piscioneri F, et al. Extracorporeal membrane oxygenation for critically ill patients with coronavirus-associated disease 2019: an updated perspective of the European experience. Minerva Cardioangiol. 2020;68(5):368–72.
Biancari F, Mariscalco G, Dalén M, Settembre N, Welp H, Perrotti A, et al. Six-month survival after extracorporeal membrane oxygenation for severe COVID-19. J Cardiothorac Vasc Anesth. 2021;35(7):1999–2006.
Thomson RJ, Hunter J, Dutton J, Schneider J, Khosravi M, Casement A, et al. Clinical characteristics and outcomes of critically ill patients with COVID-19 admitted to an intensive care unit in London: a prospective observational cohort study. PLoS ONE. 2020;15(12):e0243710.
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896–7.
Czernichow S, Beeker N, Rives-Lange C, Guerot E, Diehl J-L, Katsahian S, et al. Obesity doubles mortality in patients hospitalized for severe acute respiratory syndrome coronavirus 2 in Paris hospitals, France: a cohort study on 5,795 patients. Obesity. 2020;28(12):2282–9.
Wang J, Zhu L, Liu L, Zhao X, Zhang Z, Xue L, et al. Overweight and obesity are risk factors of severe illness in patients with COVID-19. Obesity. 2020;28(11):2049–55.
Huang Y, Lu Y, Huang Y-M, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metab Clin Exp. 2020. https://www.metabolismjournal.com/article/S0026-0495(20)30242-0/abstract. Accessed 29 May 2021.
Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity—a risk factor for increased COVID-19 prevalence, severity and lethality. Mol Med Rep. 2020;22(1):9–19.
Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin Proc. 2020;95(7):1445–53.
O’Brien JM, Phillips GS, Ali NA, Lucarelli M, Marsh CB, Lemeshow S. Body mass index is independently associated with hospital mortality in mechanically ventilated adults with acute lung injury. Crit Care Med. 2006;34(3):738–44.
Galvagno SMJ, Pelekhaty S, Cornachione CR, Deatrick KB, Mazzeffi MA, Scalea TM, et al. Does weight matter? Outcomes in adult patients on venovenous extracorporeal membrane oxygenation when stratified by obesity class. Anesth Analg. 2020;131(3):754–61.
Kon ZN, Dahi S, Evans CF, Byrnes KA, Bittle GJ, Wehman B, et al. Class III obesity is not a contraindication to venovenous extracorporeal membrane oxygenation support. Ann Thorac Surg. 2015;100(5):1855–60.
Nie W, Zhang Y, Jee SH, Jung KJ, Li B, Xiu Q. Obesity survival paradox in pneumonia: a meta-analysis. BMC Med. 2014;12(1):61.
Bein T. Driving pressure in obese ventilated patients: another brick in the (chest) wall. Intensive Care Med. 2018;44(8):1349–51.
We thank Mrs. Sabine Depetris for her help collecting the data.
This paper was not funded.
Ethics approval and consent to participate
This study was approved by the local Ethics Commission (2020-53) and the French Society of Anesthesia and Critical Care (00010254-2020-262). According to French law, the informed consent was not required due to the design of the study.
Consent for publication
CG received financial support from Xenios FMC. The other authors declare that they have no competing interests.
About this article
Cite this article
Daviet, F., Guilloux, P., Hraiech, S. et al. Impact of obesity on survival in COVID-19 ARDS patients receiving ECMO: results from an ambispective observational cohort. Ann. Intensive Care 11, 157 (2021). https://doi.org/10.1186/s13613-021-00943-0